(Q36194125)

12 August 2017

1 reference

title

Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer (English)

1 reference

12 August 2017

Pereg D

1

1 reference

PubMed ID

16018788

12 August 2017

Lishner M

series ordinal

2

1 reference

PubMed ID

16018788

12 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

Journal of Internal Medicine

12 August 2017

1 reference

12 August 2017

258

1 reference

12 August 2017

115-123

1 reference

12 August 2017

2

1 reference

12 August 2017

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Carcinogen substrate specificity of human COX-1 and COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Aspirin and the prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Aromatase and COX-2 expression in human breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Breast cancer and NSAID use: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Relation between cyclooxygenase-2 expression and tumor invasiveness and patient survival in transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Risk of lung carcinoma among users of nonsteroidal antiinflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Failing the public health--rofecoxib, Merck, and the FDA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Coxibs and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2796.2005.01519.X

10.1111/J.1365-2796.2005.01519.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference

PubMed ID

16018788